GlobeNewswire

SmartWay Logistics is Live with 3Gtms Transportation Management System

Del

Robust functionality, ability to self-configure and partnership approach drive big efficiency gains for Dutch fourth party brand

 

SHELTON, Conn., July 25, 2018 (GLOBE NEWSWIRE) -- 3Gtms, Inc., a global provider of Tier 1 transportation management software, announced that SmartWay Logistics is now live with its 3G-TM transportation management system (TMS). Headquartered in the Netherlands, SmartWay Logistics is the 4PL brand of Van der Wal, a logistics service provider with locations throughout Europe, delivering trucking, 3PL and 4PL services. SmartWay Logistics chose 3Gtms because of its powerful functionality, the ability to self-configure the TMS, and the expert reputation of the 3Gtms team.

SmartWay Logistics sought to streamline its operations by maximizing the automation of its order entering and handling. With increased automation enabled by 3Gtms, SmartWay Logistics employees have refocused their time and efforts on larger business objectives and on ensuring stellar customer service. From planning and optimization through rate management, integration, execution and payment, the company has expanded visibility into its shipments, as well as access to intuitive customer portals that improve the speed and accuracy of routing requests and order management.

Furthermore, SmartWay Logistics is leveraging the optimization power of 3Gtms to optimize in real-time and to build loads that can actually be executed, all resulting in significant cost and time savings for the company and her clients.

"Since implementing 3Gtms, we've greatly simplified the way we enter and process orders, and we have seen big gains in efficiency and cost savings by leveraging 3Gtms' powerful optimization engine," said Edwin Schouten, 4PL business unit manager. "We also value our ability to self-configure the TMS, as we need to adjust quickly to meet our customers' needs. The 3Gtms team truly understands our business and they are enthusiastic about helping us solve problems. They are a terrific partner."

"SmartWay Logistics understands the value of automation and efficiency, and their superior customer service is a result of that commitment," said Mitch Weseley, CEO at 3Gtms. "We're honored to work so closely with their team to improve their productivity and to leverage 3G-TM to address their most pressing customer challenges."

About 3Gtms
3Gtms is the fastest growing Tier 1 transportation management system (TMS) provider and is committed to giving mid-to-large shippers and logistics service providers a competitive advantage through technology. Whether you move $5 million or $5 billion in freight, the 3G-TM solution seamlessly manages the full transportation lifecycle, including transportation planning and optimization, execution and settlement, empowering customers to make better shipping decisions while meeting their service goals. 3Gtms' reputation for being a trusted partner is reflected in customer satisfaction and retention rates that are unmatched in the TMS industry. For more information, visit: www.3gtms.com.

About SmartWay Logistics
SmartWay Logistics is committed to make a serious contribution to a sustainable transport sector. Not only because it is necessary for the environment, but mainly because it produces profit. And also because it is possible: SmartWay Logistics has the knowledge, experience and technology at its disposal with which it can kick start the transition to sustainable transport. Based on continuous data analysis, SmartWay Logistics devises out of the box solutions to structurally improve transport efficiency in a smart way. This is how SmartWay Logistics pursues her audacious goal: to limit empty running to an absolute minimum.

About Van der Wal
Van der Wal was founded in 1924 by Toon van der Wal as a taxi company. The current owner, Henk van der Wal, took over the reins in 1985. The company has managed to develop into an all-round logistics service provider during the course of the past 90 years, with sites in the Netherlands, the UK, Poland, Rumania, Azerbaijan, Kazakhstan and Russia. Van der Wal has also been offering 3PL and 4PL activities for the last 10 years, in addition to the purely physical transport facilities. Van der Wal employs approximately 350 employees. For more information, visit http://www.vanderwal.company

Media Contact
Chuck Fuerst
3Gtms, Inc.
203.567.4610, x443
cfuerst@3gtms.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: 3Gtms via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi